GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

ASKA Pharmaceutical Holdings Co 4886.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

2,084

+2.86%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥71.13bn

FY2017FY2026

Net income

¥5.42bn

FY2017FY2026

Free cash flow

¥3.75bn

FY2017FY2026

Shareholders' equity

¥69.99bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue¥71.13bn¥64.14bn¥62.84bn¥60.46bn¥56.61bn¥55.18bn¥52.54bn¥46.70bn¥48.94bn¥48.53bn
Gross profit¥34.15bn¥31.34bn¥30.66bn¥28.59bn¥26.35bn¥25.38bn¥24.02bn¥18.89bn¥18.89bn¥18.91bn
Research and development¥7.06bn¥7.03bn¥4.73bn¥4.23bn¥3.60bn—¥4.91bn¥4.49bn¥4.05bn¥4.97bn
Operating income¥5.83bn¥5.33bn¥6.50bn¥5.11bn¥4.80bn¥3.61bn¥1.51bn¥1.78bn¥2.83bn¥1.79bn
Net income¥5.42bn¥5.10bn¥7.54bn¥4.24bn¥4.29bn¥2.71bn¥649.0m¥1.74bn¥2.39bn¥2.94bn
Diluted earnings per share191.05179.64266.01149.60151.7395.4822.8861.5884.56104.43

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥112.01bn¥103.25bn¥93.31bn¥87.14bn¥83.30bn¥82.58bn¥80.24bn¥82.19bn¥66.23bn¥66.13bn
Cash and short-term investments¥11.02bn¥11.16bn¥17.24bn¥17.91bn¥17.10bn¥10.51bn¥7.29bn¥11.11bn¥11.35bn¥14.76bn
Total liabilities¥35.56bn¥34.06bn¥31.38bn¥32.60bn¥34.40bn¥38.07bn¥38.66bn¥38.74bn¥23.67bn¥26.61bn
Debt¥11.43bn¥10.90bn¥9.48bn¥12.62bn¥14.05bn¥16.39bn¥16.42bn¥16.47bn¥2.95bn¥3.70bn
Shareholders' equity¥69.99bn¥65.31bn¥61.93bn¥54.53bn¥48.89bn¥44.51bn¥41.57bn¥43.46bn¥42.56bn¥39.51bn
Shares outstanding28m28m28m28m28m28m28m28m28m28m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations¥6.30bn¥2.48bn¥1.49bn¥3.35bn¥2.84bn¥6.54bn−¥492.0m¥2.50bn¥76.0m¥12.06bn
Capital spending−¥2.55bn−¥2.96bn−¥1.32bn−¥746.0m−¥2.38bn−¥1.10bn−¥2.06bn−¥2.35bn−¥744.0m−¥690.0m
Free cash flow¥3.75bn−¥475.0m¥166.0m¥2.60bn¥465.0m¥5.44bn−¥2.55bn¥154.0m−¥668.0m¥11.37bn
Dividends paid−¥1.62bn−¥1.27bn−¥792.0m−¥452.0m−¥398.0m−¥484.0m−¥398.0m−¥395.0m−¥392.0m−¥390.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥17.38bn¥16.64bn¥19.23bn¥17.61bn¥17.64bn¥14.21bn¥17.55bn¥16.02bn
Gross profit¥8.09bn¥7.82bn¥9.34bn¥8.36bn¥8.63bn¥6.88bn¥8.55bn¥7.74bn
Operating income¥711.0m¥922.0m¥2.26bn¥1.17bn¥1.48bn−¥163.0m¥2.15bn¥1.59bn
Net income¥533.0m¥1.52bn¥1.68bn¥982.0m¥1.25bn¥1.00bn¥1.54bn¥1.29bn
Diluted earnings per share18.7753.5359.0934.5843.8435.3254.2245.37
Total assets¥109.91bn¥112.01bn¥112.70bn¥108.77bn¥102.95bn¥103.25bn¥91.49bn¥88.26bn
Cash and short-term investments¥7.11bn¥11.02bn¥6.58bn¥7.45bn¥7.23bn¥11.16bn¥10.17bn¥13.71bn
Debt¥4.16bn¥11.43bn¥5.06bn¥12.63bn¥4.24bn¥10.90bn¥4.18bn¥7.64bn
Shareholders' equity¥70.77bn¥69.99bn¥68.74bn¥66.86bn¥65.44bn¥65.31bn¥65.19bn¥64.19bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.6%5.2%5.1%
Operating income4.5%10.1%17.5%
Net income8.6%14.9%22.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin48.4%48.2%47.6%44.9%
Operating margin8.3%8.8%8.4%6.6%
Net margin7.8%8.6%7.9%6.2%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings11.011.37.911.98.610.669.720.513.119.1
Price to sales0.80.90.90.80.70.50.90.80.61.2

Dividends and splits

Per share, in the currency the company pays

Paid for 36 years. Last went ex-dividend on 29 Sept 2026.

FY2027FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Paid in the year32.0085.0045.0028.0016.0014.0014.0014.00
  • 1-to-1 reverse split · 1 Oct 2005

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.